Objective Anti-myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)-related nephritis constitutes 60% of rapidly progressive glomerulonephritis (RPGN) in Japan. The reported 1-year survival rate is over 80%, however, the long-term prognosis remains unknown. We therefore investigated the prognosis and factors affecting the clinical course of patients. Methods We retrospectively investigated 74 patients (female, n=42; median age, 73.0 years) with MPO-ANCA-related nephritis. The patients were admitted to Fukushima Medical University and two affiliated hospitals between 2000 and 2010. Results Median estimated GFR (eGFR) was 12.1 mL/min/1.73 m 2 at admission. The Birmingham Vasculitis Activity Score (BVAS version 3: max 63 points) at diagnosis and at 4 weeks after start of treatment were 15.0 and 5.0, respectively. Twenty-three patients (31%) died during a median observation period of 30.5 months. Sixteen patients (22%) presented with end-stage renal disease (ESRD) at the initial phase, and needed regular dialysis therapy. Multivariate Cox proportional hazards model analysis revealed that renal death at the initial phase was a significant risk factor for all-cause death (Hazard ratio, 5.72; 95% confidence interval, 2.49-13.09; p<0.001). Furthermore, BVAS>6, evaluated 4 weeks after start of treatment, is an independent risk factor for ESRD and patient survival. Conclusion This is the first investigation to demonstrate clinical features focusing on MPO-ANCA-related nephritis. Renal death at the initial phase of treatment is a powerful risk factor for all-cause death in patients with MPO-ANCA-related nephritis. Patients at high risk of death and ESRD could be stratified according to BVAS.
presence of ANCA. MPO-ANCA-related nephritis constitutes 60% of RPGN that occurs in Japan, while nearly 90% of patients with MPA and RLV presented MPO-ANCA positive. The reported 1-and 2-year outcomes of Japanese RPGN showed survival of 83% and 78%, and renal survival of 81% and 77%, respectively (1, 2) . Those prognoses seem to be identical to those of MPA patients in Europe with a 77-100% 1-year survival (3) (4) (5) . However, the long-term prognosis in clinical forms of MPO-ANCA-related nephritis remains unknown.
Age, pulmonary involvement and renal function at diagnosis have been identified as traditional risk factors for patient survival in ANCA-associated vasculitides. The renal function diagnosed then has also been traditionally considered as a risk factor for renal survival. Furthermore, factors such as, higher CRP, higher white blood cell count (WBC), lower hemoglobin (Hb), lower albumin and an initial dose of prednisolone (PSL) of >0.8 mg/kg/day have also been pointed out as risk factors for patient survival (2, 3, (6) (7) (8) (9) .
The Birmingham Vasculitis Activity Score (BVAS) was validated for the assessment of disease activity in systemic vasculitides in 1994, and thereafter it was followed by sequential development to the present BVAS version 3 (10, 11) . Recently, BVAS has been recognized not only as an evaluation tool for disease activity but also as a prognostic factor for patient survival in vasculitides (6, (12) (13) (14) . As of yet, however, BVAS has not been sufficiently established as a prognostic factor for MPO-ANCA-related nephritis.
Therefore, in this retrospective study, we firstly reviewed the clinical course of patients with MPO-ANCA-related nephritis, and secondly, investigated prognostic factors for patient and renal survival, with special attention to BVAS.
Materials and Methods

Patient selection and inclusion criteria
Seventy-four patients [female, n=42; mean age, 73.0 (66.0-77.0) years] were included in this retrospective study (Table 1) . They were admitted Fukushima Medical University Hospital (Fukushima City, Japan) and two affiliated hospitals (Ohta General Hospital, Koriyama City, Japan, Fujita General Hospital, Kunimi Town, Japan) during the period between 2000 and 2010. Inclusion criteria for the study were: 1) Positive serology for MPO-ANCA, 2) Renal involvement (rapidly elevated serum creatinine, and/or the presence of hematuria: >10 red blood cells per high power field, and/or red cell casts, and/or proteinuria: >0.5 g/gCreatinine), and 3) New onset vasculitis was categorized as MPA by Watts' algorithm, and histological confirmation was not required. We classified the type of vasculitides such as CSS, GPA, MPA and classical polyarteritis nodosa (PAN) using the algorithm (15) . All participants in this study had MPO-ANCA positive nephritis, including renal limited vasculitis, and were categorized as MPA by this algorithm.
Clinical features, laboratory findings at diagnosis, initial phase treatment and outcomes of the full observation period in this study are shown in ); consistent with small vessel vasculitis both clinically and histologically, with no GPA surrogate markers. The other 53 patients (71.6%) were classified as MPA (3b) with positivity for ANCA with no GPA surrogate markers, suggestive of granulomatous disease in the upper and lower respiratory tract, which also includes RLV, and no histological confirmation was required. There was no set treatment protocol in this study, therefore therapeutic regimens were individually adjusted depending on the condition of the patients' disease. Nearly half of the patients were treated by oral PSL alone and the initial dose of PSL was 30.0 (20.0-40.0) mg/day. The dose based on weight was 0.63 mg/kg/ day. Methylprednisolone pulse therapy (500 to 1,000 mg/day for 3 consecutive days) was additionally given to 27 patients (36.5%). Methylprednisolone pulse therapy and cyclophosphamide were added for 9 patients (12.1%). Five patients (6.8%) additionally received a short course of plasma exchange.
Analysis
The clinical outcomes of these 74 patients were retrospectively analyzed from the medical records. The principal outcomes in this study were ESRD and death. All patients were followed until their death or the last clinical encounter, and patients who dropped out mid-course were excluded. "Nonsurvivor" was defined as any patient who died regardless of cause of death, and survivor was defined as any patient who could avoid all causes of death within the investigation period. ESRD was defined as the initiation of renal replacement therapy (regular dialysis therapy). Remission was defined as recovery and stabilization of renal function and disappearance of extrarenal complication due to vasculitis. For the patients on dialysis, laboratory data of CRP and WBC were also used as reference. BVAS was basically 0 or 1 point in the remission phase. Relapse was defined as deterioration of renal function with nephritic urinary findings, or exacerbation of extrarenal complications and/or newlyoccurred extrarenal complications. BVAS is evaluated over 1 point continuously in the relapse phase. Essentially, relapse of vasculitis requires intensification of treatment, for example, increasing steroid dose, or adding immunosuppressive agents.
We assessed disease activity using the latest BVAS version 3 (11) and evaluated the score twice; at diagnosis and at 4 weeks after starting therapy. Laboratory data evaluated in this study are as follows; sCre, eGFR, CRP, Hgb, MPO- ANCA, PR3-ANCA, anti-GBM antibody, uric blood (uBld), and uric protein (u-Pro). MPO-ANCA and PR3-ANCA were measured by enzyme-linked immunosorbent assay. We graded uric red blood cell count as follows: Grade 1 is U-RBC<10 per high power field (HPF), Grade 2 is 10! U-RBC<20, Grade 3 is 20! U-RBC<30, Grade 4 is 30! U-RBC <50, Grade 5 is 50! U-RBC<100, and Grade 6 is 100! U-RBC.
Statistical analysis
All data are presented as medians (interquartile range, IQR) or means (standard deviation, SD), as appropriate for Figure 1 . Incidence of organ affection in the 9 BVAS categories. All patients who had renal involvement were frequently followed with pulmonary involvement (n=29, 39%), systematic sign for vasculitis such as fever, weight loss, arthritis (n=26, 35%), and neurological involvement (n=11, 15%).
nonparametric or parametric variables. Nonparametric variables were compared using the Mann-Whitney U test. Both patient and renal survival were assessed using the KaplanMeier method and multivariate Cox proportional hazards model to identify independent risk factors. In this analysis, we preliminarily confirmed that there was no multicollinearity. Multivariate Cox proportional hazards model analysis was performed by step-up procedure and likelihood ratio test. We also used receiver-operating characteristic (ROC) curves of sensitivity plotted against 1-specificity to detect the most influential points for outcomes. All statistical analyses were performed in SPSS (version 19.0, SPSS, Inc., Chicago, IL). Association with p<0.05 was considered to be statistically significant.
Results
Primary outcomes
Twenty-three patients (31%) died during the observation period due to infection [n=8; acute pneumonia (3 patients), aspiration pneumonitis (2 patients), pulmonary aspergillosis (1 patient), urinary-tract infection (1 patient) and sepsis (1 patient)], recurrent vasculitis (n=4), heart failure (n=4), cancer (n=2), cerebrovascular accident (n=2) and other causes. Survival rates at 1-, 2-and 5-years were 85.4%, 75.4% and 48.7%, respectively. Twenty-seven patients (37%) reached ESRD and of those, 16 patients required maintenance hemodialysis from the initial phase of treatment. Renal survival rates of 1-, 2-and 5-years were 68.3%, 63.6% and 34.3%, respectively.
BVAS at diagnosis and at 4 weeks after starting treatment were 15.0 (12.0-19.0) and 5.0 (2.5-7.0) points, respectively. Incidence of affected organs in the 9 BVAS categories is shown in Fig. 1 . In patients with renal involvement it was frequently followed with pulmonary involvement (n=29, 39%), systematic sign for vasculitis such as fever, weight loss, arthritis (n=26, 35%), and neurological involvement (n=11, 15%). BVAS evaluated 4 weeks after start of treatment was a similar to the BVAS obtained at diagnosis, indicating elongation of renal, pulmonary and neurological involvement.
Thirteen patients had recurrence of vasculitis (a total number of 17 times). The dosage of PSL at recurrence was 10.0 (5.0-15.0) mg/day and the length of time from starting treatment to recurrence was 15.0 (4.0-33.0) months.
Risk factors for renal and life prognosis
Characteristics among groups of survivors and nonsurvivors, and non-renal deaths and renal deaths were compared and are shown in Table 2 . Risk factors for patient survival are assumed to be age, BVAS evaluated at diagnosis and 4 weeks after the start of treatment, sCr, eGFR, and uPro. Risk factors for renal death are assumed to be preexisting CKD, BVAS evaluated 4 weeks after start of treatment, sCr, eGFR, and u-Pro. The number of renal deaths at the initial phase was 4 (7.8%) in the survivor group, and 12 (52.1%) in the non-survivor group. Multivariate Cox proportional hazards model analysis revealed that renal death at the initial phase was a significant risk factor for all-cause death (Hazard ratio (HR), 5.72; 95% confidence interval (CI), 2.49-13.09; p<0.001). Patient survival according to the presence of renal death at the initial phase, is shown in Fig. 2 (Log Rank test, p<0.001). In multivariate analysis, BVAS evaluated 4 weeks after the start of treatment, eGFR and age constituted independent risk factors for patient survival (Table 3). Pre-existing CKD, BVAS evaluated 4 weeks after the start of treatment and eGFR constituted independent risk factors for renal death (Table 4) . Fig. 3 shows the correlation among BVAS evaluated at 4 weeks, eGFR and patient survival and renal survival by estimation of the area under the ROC curve. Estimated GFR< 12.0 and <10.5 mL/min/1.73 m 2 were risk factors for patient survival (the area under ROC curve=0.781, 95% CI, 0.679-0.883; p<0.001) and renal survival (the area under ROC curve=0.807, 95% CI, 0.699-0.915; p<0.001), respectively. BVAS >6 evaluated at 4 weeks after therapy is an independent risk factor for renal death (the area under ROC curve (AUC) =0.786, 95% CI, 0.670-0.902; p<0.001) and patients' survival (area under ROC curve=0.855, 95% CI, 0.768-0.941; p<0.001).
Relationships between steroid pulse therapy and outcomes are shown in Fig. 4 . Five (13.9%) of 36 cases with steroid pulse therapy reached ESRD at the initial phase and 11 (28.9%) of 38 cases without steroid pulse therapy reached ESRD at the initial phase. Three (12.5%) of 25 cases with steroid pulse therapy died within one year and 6 (16.2%) of 37 cases without steroid pulse therapy died within one year. The relations between steroid pulse therapy and initial renal death, and the therapy and survival within one year were not statistically significant. 
Discussion
The previous study, which compared patients' background regarding ANCA-related vasculitides in Japan and U.K., confirmed higher age (72 vs. 61 years), predominant subtype of MPA, and less in GPA in Japanese. In addition, ANCA pattern revealed that 80% of subjects presented with MPO-ANCA, while about 30% of those in the U.K. presented with PR3-ANCA (8) . In the present study, higher age, predominant subtype on MPA, and ANCA pattern were common among the patients. We firstly reviewed the clinical course of MPO-ANCA-related nephritis in our subjects with special attention to clinical relevance to BVAS. We showed independent risk factors for life and renal outcomes, such as advanced age, initial renal death, high BVAS at the initial phase and pre-existing CKD. Another European research, which focused on the long-term prognosis of ANCA associated vasculitides (All n=535, MPA n=254, GPA n=281, mean age: 61 years), revealed that 1-, 2-, and 5-year patient survival rates were 88%, 85%, and 78%, respectively. According to the research, the significant negative risk factors for survival were advanced age, eGFR<15, higher BVAS, lower Hgb, and higher WBC (6) . However, in our study, survival rates at 1-, 2-and 5-years were 85.4%, 75.4% and 48.7%, respectively. And, renal survival rates of 1-, 2-and 5-years were 68.3%, 63.6% and 34.3%, respectively.
Higher age is an independent risk factor for patient survival, and previous reports demonstrated that the elderly subjects were closely related with significantly higher rates of death, ESRD, and more treatment related complications than younger patients (9, 16, 17) . Renal death at the initial phase of treatment is a powerful risk factor for all-cause deaths in the study subjects (Fig. 2) , and which is consistent with previous reports (2, (6) (7) (8) (9) . Less than 12 mL/min/1.73 m 2 of eGFR value was correlated with a significant poor life prognosis, while less than 10.5 mL/min/1.73 m 2 of eGFR value was correlated with a significant poor renal prognosis (Fig. 3) . Regarding the causes of death in 23 cases, a major cause of death was treatment related infection, followed by pulmonary involvement of vasculitis in the cases of death within 2 years, whereas CVD, followed by cancer was the major cause for death in the cases after 2 years. No differences were observed in the disease form, and the initial dose of PSL.
Elderly patients sometimes present with severe renal failure after the initial visit and are often resistant to therapy (18) . Furthermore, mortality of MPA among the elderly is higher than GPA (19, 20) , therefore, earlier detection and initiation of treatment is very important. In the present study, 8 (88.9%) of 9 subjects who had pre-existing CKD finally developed ESRD and died. This may suggest that CKD worsens prognosis in MPO-ANCA-related nephritis indirectly through ESRD status. We think there are two major reasons why the survival rate of our results were lower compared to a previous study in Europe; one is higher age, and the other is lower renal function. Age difference was over 10 years when comparing our data vs. European research: 72 vs. 61 years, and renal function in our research was lower than half when comparing our data vs. European research of eGFR: 12.1 vs. 27.9 mL/min/1.73 m 2 (6) . The reason behind these differences is that the majority of ANCA-related vasculitides in the previous study in Europe was GPA which was dominated by serologically PR3-ANCA-positive patients.
The previous retrospective study, which included 73 Japanese MPA patients, showed that a higher BVAS (over 16 points) was correlated with shorter survival time and higher mortality rate (14) . In the present study, we were able to stratify patients at high risk of death and ESRD by BVAS. It is suggested that serial evaluation of BVAS could be beneficial for predictive factor of death, as reported elsewhere (12) . BVAS evaluated at 4 weeks after start of therapy was identified as an independent predictive factor for death and ESRD; BVAS of higher than 6 points correlated significantly with poor renal and life prognosis (Fig. 3) . This cut-off point was assessed by the ROC curve, and AUC for renal death was 0.786, and also AUC for patients' survival was 0.855. Treatment-resistant vasculitis especially pulmonary bleeding, interstitial pneumonitis and progressive renal dysfunction due to disease activity contributed to the BVAS after the start of therapy. This result suggests the significance of serial assessment of BVAS as markers of treatment response and predictive indicators for prognosis.
BVAS at the initial visit tended to be higher in the nonsurvivor group (14 vs. 18 points), however it showed no significant difference in multivariable analysis.
As standard therapeutic regimens for MPO-ANCA-related nephritis have not been established, treatment is individually adjusted depending on disease condition. Strong immunosuppressive therapy has a casual influence on patient survival, and is sometimes difficult in patients with MPO-ANCA-related nephritis due to advanced age (2, 3, 21, 22) . In a recently reported study from the US, immunosuppressive therapy improved the incidence of ESRD 1 year after renal biopsy compared to untreated patients (36 vs. 73%) in very elderly patients (over 80 years) with ANCA-associated pauci-immune glomerulonephritis (23) . Moreover, the researchers demonstrated that immunosuppressive therapy was effective to lower the risk of death (HR 0.33, 95%CI 0.11-0.97) based on their 2-year follow-up. This suggests that some immunosuppressive therapy is necessary even for very elderly patients. In the study, many patients were treated with oral PSL alone or oral PSL plus methylprednisolone pulse therapy at a dose of 500-1,000 mg/day for 3 consecutive days, and cyclophosphamide was less frequently used (n=9, 12%), which was similar to the Japanese RPGN registry (2). Methylprednisolone pulse therapy had no additive effects on renal survival at the initial phase and survival at 1 year in our study. Although, we could not identify factors to improve prognosis, and the pre-existing CKD cases in particular had a poor 1-year renal life prognosis. The immunosuppressive regimen and its impact need to be addressed.
There are two limitations to this study. First, it was a retrospective analysis and second, there was no therapeutic regimen design. Only 7 (30.4%) of 23 death cases had undertaken renal biopsy as most of the patients had a poor general status caused by systemic inflammation and infection. Therefore, we could not manage patients for whom a biopsy was not undertaken. Further detailed investigations to improve renal and life prognosis by providing the best care based on characteristics of MPO-ANCA-related nephritis are necessary.
Conclusion
This is the first investigation to demonstrate the clinical features of MPO-ANCA-related nephritis. Renal death at the initial phase of treatment is a powerful risk factor for allcause death in patients with MPO-ANCA-related nephritis. Patients at high risk of death and ESRD could be stratified according to BVAS.
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